Vitoria Da Conquista

Researchers are investigating whether patients with locally advanced cervical cancer who still have detectable cell-free human papillomavirus DNA cfHPV-DNA in their plasma after standard treatment may benefit from additional chemotherapy. This trial is a prospective, randomized, multicenter clinical study designed to evaluate adjuvant chemotherapy based on this biomarker. The study focuses on patients who have undergone chemoradiotherapy and have persistent cfHPV-DNA, as this may indicate ongoing disease activity. Participants first receive standard treatment with concomitant chemoradiotherapy, including doses of radiation and weekly cisplatin. Four weeks after completing this treatment, a blood test is conducted to detect cfHPV-DNA in plasma. Patients with positive cfHPV-DNA results are randomly assigned to either receive two additional cycles of adjuvant chemotherapy with cisplatin and gemcitabine or to be monitored without further chemotherapy. Patients in both groups undergo regular follow-up every four months, including plasma cfHPV-DNA testing, CT scans of the chest, MRI scans of the abdomen and pelvis, and clinical and gynecological exams. During the study, participants are closely monitored for progression-free survival, overall survival, treatment response, quality of life, and any toxic effects of treatment. Follow-up assessments occur at regular intervals from 7 to 120 days after treatment. The total duration of participant involvement varies based on follow-up schedules. The study uses a single-blind design and randomized allocation to ensure scientific rigor while maintaining patient safety throughout the trial period.

This research aims to map breast and prostate cancer in patients treated through the Brazilian Unified Health System by performing complete sequencing of tumor somatic and germline exomes. It focuses on understanding molecular variants in tumors, which can affect treatment response and disease prognosis. The project also seeks to identify hereditary genetic syndromes and collect data on the populations ancestry for the Brazilian Ministry of Healths National Precision Genomics and Health Program, Genomas Brasil. The study includes two groups 745 patients with HER2-positive and triple-negative breast cancer who underwent neoadjuvant therapy followed by surgery, and 137 patients with metastatic prostate cancer. Sequencing involves somatic and germline whole exome analysis for prostate and HER2-positive breast cancer, and somatic whole exome with germline whole genome sequencing for triple-negative breast cancer. Participants will provide tumor tissue and blood samples for genomic analysis. Researchers will characterize complete somatic and germline exomesgenomes within 12 months, identify genetic variants related to tumor prognosis and treatment response, and count patients with mutations in cancer-predisposing genes. The study runs until 2026 and data will support precision oncology efforts in Brazil.

Researchers are evaluating the effectiveness of a pharmaceutical care protocol delivered via teleconsultation compared to in-person pharmaceutical care in managing uncontrolled hypertension in elderly patients. This study aims to understand how well telepharmacy supports clinical outcomes and treatment adherence for older adults with high blood pressure. It also explores patient satisfaction and the clinical impact of pharmacist interventions. Participants will be randomly assigned to receive either pharmaceutical care through telepharmacy or traditional in-person care. The study involves four visits two visits for initial and final assessments of clinical parameters and application of instruments, conducted in a pharmacy setting by trained pharmacists and students and two visits for pharmaceutical consultations, which will be either teleconsultations or face-to-face sessions, depending on group assignment. During the study, researchers will measure blood pressure control, medication adherence, patient satisfaction, and the clinical significance of pharmacist interventions over a three-month period. Participants will have their blood pressure measured using a standardized protocol, and their treatment adherence and satisfaction will be evaluated. The study is sponsored by the Federal University of Bahia and is expected to complete by March 2026.